Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.49 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.48 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003204 | 1.00 | SLC9A1 (0.67) | SLC9A1HTR2AHTR2CHTR2BFFAR1 | |
| SCHEMBL10288769 | 1.00 | SLC9A1 (0.67) | SLC9A1HTR2AHTR2CHTR2BFFAR1 | |
| SCHEMBL7003208 | 1.00 | SLC9A1 (0.67) | SLC9A1HTR2AHTR2CHTR2BFFAR1 | |
| SCHEMBL21501023 | 1.00 | SLC9A1 (0.67) | SLC9A1HTR2AHTR2CHTR2BFFAR1 | |
| SCHEMBL1207144 | 1.00 | SLC9A1 (0.67) | SLC9A1HTR2AHTR2CHTR2BFFAR1 | |
| SCHEMBL8357586 | 0.88 | SLC9A1 (0.67) | SLC9A1HTR2AHTR2CHTR2BGPR88 | |
| SCHEMBL30997748 | 0.86 | SLC9A1 (0.73) | SLC9A1HTR2AHTR2CHTR2BGPR88 | |
| SCHEMBL7006240 | 0.84 | FFAR1 (0.62) | SLC9A1FFAR1 | |
| SCHEMBL9385280 | 0.84 | FFAR1 (0.62) | SLC9A1FFAR1 | |
| SCHEMBL6326088 | 0.84 | SLC9A1 (0.62) | SLC9A1HTR2AHTR2CHTR2BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | SLC9A1 4428/4885HTR2A 3223/4885HTR2C 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.